Via Scientific, a Boston, MA-based a pioneering company at the forefront of revolutionizing life science research.
Via Scientific was funded $5 million, this substantial financial backing is poised to propel the company’s mission to expedite the pace of discovery in the field of life science. The funding round was led by G20 Ventures and Innospark Ventures. The syndicate also included Life Science and AI Angel investors including Melissa J. Moore, former CSO of Moderna, Rob Hickey, Former EVP at DataRobot, and Janet Kosloff, Founder, and former CEO of InCrowd, Inc.
Via Scientific’s groundbreaking approach and vision for transforming the landscape of scientific discovery garnered substantial interest from investors seeking to support cutting-edge advancements in the field. Specializes in leveraging advanced technologies, including artificial intelligence and machine learning, to revolutionize the process of drug discovery and development. Their proprietary platform harnesses the power of data analytics and computational biology, enabling researchers to expedite the identification and validation of potential drug candidates with unprecedented efficiency.
Jim Crowley Via Scientific CEO said, that they are thrilled by the support and confidence shown by their investors, which reflects the recognition of their commitment to transforming life sciences research. For him the funding will significantly accelerate their efforts to bring about meaningful advancements in drug discovery, ultimately impacting patient care and healthcare outcomes.
The infusion of capital will primarily fuel the expansion of Via Scientific’s research and development efforts. The company plans to enhance its technological infrastructure, further refine its AI algorithms, and broaden its collaborations with pharmaceutical partners and research institutions.
Via Scientific’s innovative approach aims to streamline the traditionally laborious and time-consuming process of drug discovery, potentially expediting the development of life-saving treatments for various diseases.
This significant funding milestone marks a pivotal moment for Via Scientific, providing the resources needed to push the boundaries of life sciences research and bring forth novel therapeutic solutions that could positively impact global healthcare.
By: K. Tagura
Author statement:
Who we are: Funded.com is a platform that is A+ BBB accredited over 10+ years. Access our network of Angel Investors, Venture Capital or Lenders. Let us professionally write your Business Plan.
Rss Feed
